- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01429012
Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting
Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting. A Randomized, Double-blind, Controlled Study
Bone fractures heal most of the time particularly well and without complications. The solidification takes rarely more than two to three months. The wound healing depends greatly on a good blood supply and needs several steps. These processes culminate in a new mass of heterogeneous tissue which is known as the fracture callus. Unfortunately, 2%-5% bone fractures cannot achieve a proper solidification and between the ununited fragments a scar tissue appears. This incorrect healing induces pain and even infections. When this situation persists more than 6 months, it is referred to as nonunion fracture, which will require some form of intervention to stimulate the natural healing process of the body. First of all, good surgical techniques with stable immobilization should be applied and local infection should be excluded. Then stimulation of the callus is required. Cell therapy with bone marrow cells has emerged as a promising new approach for bone regeneration. Animal studies as well as preliminary human studies have shown that Mesenchymal Stem Cells, a particular kind of stem cells isolated from the bone marrow, could induce callus formation when injected in the nonunion site of a broken bone.
In this study the investigators aim at determining whether Mesenchymal Stem Cells (MSC) isolated from the patient's bone marrow and injected in the nonunion site could be a safe and effective treatment for nonunion fractures. Patients will be randomized in two groups; one injected with Mesenchymal Stem Cell and the other injected with placebo. The investigators seek also to know how long it takes to develop the callus formation and whether there is a partial or a complete callus formation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Liège, Belgium, 4000
- Liege University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female; female patients must use a reliable contraception method
- Age ≥ 18 years
- Fracture having no radiological callus after 6 months and absence of any hypertrophic bone reaction.
- No sepsis
- Good skin covering
- Be able and willing to participate in the study
- Written informed consent
Exclusion Criteria:
- Evidence of malignancy (except non-melanoma skin cancer) in the past five years
- Pregnancy or breastfeeding
- Patient positive by serology or PCR for HIV, hepatitis B or C infection
- Insufficient reduction of the fracture with displaced fragments
- Evidence of local sepsis by clinical signs, biological parameters (CRP) and/or positive isotopic scan using Indium-labelled leucocytes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Mesenchymal Stem Cells
2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture. MSC will be injected even if the number of available cells is lower than 40 X 10E6. The injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist. |
Mesenchymal Stem Cells.
Dose= 40 X 10E6 in 2 ml.
Frequency = one injection.
If no evidence of a callus after 6 months a second injection can be proposed.
Other Names:
|
PLACEBO_COMPARATOR: Culture medium without MSC.
Culture medium used to resuspend the Mesenchymal Stem Cells.
|
2 ml of culture medium.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Mesenchymal Stem Cells injection in nonunion fractures.
Time Frame: 12 months
|
Follow-up for revealing any significant immediate or late adverse effects.
|
12 months
|
Proportion of patients receiving Mesenchymal Stem Cells that develop a partial or complete callus at 6 and 12 months, compared to patients receiving placebo.
Time Frame: 6 and 12 months
|
Radiological evaluation of the callus by standard X-rays and computed tomography (CT).
|
6 and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients receiving Mensechymal Stem Cells that develop a partial or complete callus at 2, 3, 4, 8 and 10 months, compared to patients receiving placebo
Time Frame: 2, 3, 4, 8 and 10 months
|
Radiological evaluation of the callus by standard X-rays and computed tomography (CT).
|
2, 3, 4, 8 and 10 months
|
Timing of development of a partial or complete callus in the 2 groups.
Time Frame: 12 months for one injection or 18 months when a second injection is needed
|
Time necessary for a partial or a complete callus formation.
Radiological evaluation of the callus by standard X-rays and computed tomography (CT).
|
12 months for one injection or 18 months when a second injection is needed
|
Patient evaluation of pain and global satisfaction.
Time Frame: 12 months
|
This evaluation will be measured through a 100-mm Visual Analogue Scale at 2, 3, 4, 6, 8, 10 and 12 months in the 2 groups.
|
12 months
|
Proportion of patients achieving different degrees of functional success.
Time Frame: 2, 3, 4, 6, 8, 10 and 12 months
|
The functional assessment will be evaluated in Mesenchymal Stem Cells treated and untreated patients by an orthopaedic surgeon and will include a 4-points scale:
|
2, 3, 4, 6, 8, 10 and 12 months
|
Incidence of adverse events and severe adverse events in the 2 groups.
Time Frame: 12 months for one injection and 18 months when a second injection is performed
|
Adverse events and serious adverse events will be continuously monitored .
|
12 months for one injection and 18 months when a second injection is performed
|
Evaluation of early homing of Mesenchymal Stem Cells.
Time Frame: 24 hours
|
Indium radiolabeled Mesenchymal Stem Cells (MSC) will be visualized with a Siemens e-CAM dual head gamma camera: 10% of the total amount of MSC will be incubated with 200 µCi In-111-oxine.
The radiolabelled cells will be mixed with the unlabelled ones.
Twenty-four hours after injecting the cells into the target bone lesion, static images centered over the injection site and whole-body images will be acquired during 20 minutes.
This will be performed with a Siemens e-CAM dual head gamma camera.
|
24 hours
|
Value of [18F]-NaF PET scans for early prediction of the onset of the bone healing process.
Time Frame: 3 months
|
PET Fluor kinetics could identify early and perhaps quantify the increase of bone forming in the treated area.
Four [18F]-NaF PET scan studies will be performed: at baseline, as well as around days 7-9 (1 week), 27-33 (one month) and 83-97 (three months).
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean Philippe Hauzeur, MD, PhD, University of Liège
- Study Chair: Yves Beguin, Prof, MD, PhD, University of Liège
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJT1101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonunion Fracture
-
Zimmer BiometTerminatedNonunion of Fracture of Fifth MetatarsalUnited States
-
Cedars-Sinai Medical CenterStryker NordicCompletedTibial Fractures | Nonunion of Fracture | Femur Fracture | Tibia Fracture | Nonunion of Fracture of Tibia | Nonunion of Fracture of Femur (Diagnosis)United States
-
Banc de Sang i TeixitsHospital ASEPEYO Sant CugatCompletedAtrophic Nonunion of FractureSpain
-
Saglik Bilimleri UniversitesiCompletedNonunion of Fracture of Tibia | Tibia Distal FractureTurkey
-
Istituto Ortopedico RizzoliCompletedNonunion of Fracture [Pseudarthrosis], Site UnspecifiedItaly
-
Royan InstituteCompletedNonunion FracturesIran, Islamic Republic of
-
Second Affiliated Hospital, School of Medicine,...CompletedNonunion of Fracture of Tibia (Diagnosis)China
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaUnknownNonunion FractureChina
-
Herlev and Gentofte HospitalRecruitingScaphoid Fracture | Scaphoid NonunionDenmark
-
Aesculap AGTerminatedSternum Wound Infection | Nonunion of Fracture of SternumGermany, Switzerland
Clinical Trials on Mesenchymal Stem Cells
-
Guangzhou General Hospital of Guangzhou Military...UnknownSpinal Cord InjuryChina
-
Guangzhou General Hospital of Guangzhou Military...Guangzhou Municipal Twelfth People's Hospital; Guangdong Prevention and Treatment...Unknown
-
Guangzhou General Hospital of Guangzhou Military...UnknownParkinson's DiseaseChina
-
Hospital ZnojmoUnknown
-
National Research Center for Hematology, RussiaUnknownRelapse | Graft-versus-host DiseaseRussian Federation
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
Qingdao UniversityUnknownDilated CardiomyopathyChina
-
Qingdao UniversityUnknownUlcerative Colitis | Mesenchymal Stem Cells | Umbilical CordChina
-
Qingdao UniversityUnknownDiabetes Mellitus | Diabetes Mellitus, Type 1 | Mesenchymal Stem Cells | Umbilical CordChina
-
Universidad Catolica Santiago de GuayaquilMaastricht University Medical CenterUnknownOsteo Arthritis KneeEcuador